4.64
+0.03(+0.65%)
Currency In USD
| Previous Close | 4.61 |
| Open | 4.51 |
| Day High | 4.73 |
| Day Low | 4.51 |
| 52-Week High | 14.6 |
| 52-Week Low | 3.83 |
| Volume | 554,146 |
| Average Volume | 759,892 |
| Market Cap | 254.74M |
| PE | -7.03 |
| EPS | -0.66 |
| Moving Average 50 Days | 5.32 |
| Moving Average 200 Days | 6.07 |
| Change | 0.03 |
If you invested $1000 in Candel Therapeutics, Inc. (CADL) since IPO date, it would be worth $662.86 as of November 16, 2025 at a share price of $4.64. Whereas If you bought $1000 worth of Candel Therapeutics, Inc. (CADL) shares 3 years ago, it would be worth $2,494.62 as of November 16, 2025 at a share price of $4.64.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Candel Therapeutics Showcases Immunotherapy Leadership at SITC 2025, Demonstrating Integration of Clinical Innovation, Multi-Omics, and Artificial Intelligence to Advance Next-Generation Immunotherapies in Solid Tumors
GlobeNewswire Inc.
Nov 04, 2025 2:00 PM GMT
Invited presentation followed by panel discussion on the next wave of innovation in immunotherapy of cancer: Paul Peter Tak, M.D., Ph.D., FMedSci, Candel’s President and CEO, will present the phase 3 clinical trial of CAN-2409 in newly diagnosed, loc
Candel Therapeutics to Present at Jefferies Global Healthcare Conference in London
GlobeNewswire Inc.
Nov 03, 2025 1:05 PM GMT
NEEDHAM, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer
Candel Therapeutics Appoints Leading Systems Immunology Expert Bali Pulendran, Ph.D., to Research Advisory Board
GlobeNewswire Inc.
Oct 16, 2025 12:05 PM GMT
NEEDHAM, Mass., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer